Apogee Therapeutics Inc APGE R2KR3KPHARMA
Company Overview
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +261.54% |
| 6 Months: | +90.45% |
| 3 Months: | +48.59% |
| 1 Month: | +0.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)78.61 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 79 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | APGE Apogee Therapeutics Inc R2KR3KPHARMA | 135.07 | -31.12 | $8.40B | 0.00% | -31.41% | -32.46% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 63.10M | 73.17M | 71.28M | 78.06M | 82.77M | - |
| Operating Income | -1.82M | -10.51M | -12.66M | -18.89M | -24.30M | -38.18M | -44.12M | - | -63.10M | -73.17M | -71.28M | -78.06M | -82.77M | -96.00M |
| EBITDA | - | - | - | - | - | - | - | - | -62.89M | -72.77M | -70.87M | -77.65M | -82.36M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | -55.26M | -66.02M | -64.96M | -69.33M | -74.03M | - |
| Tax Provision | - | - | - | - | - | - | - | - | 83.00K | 72.00K | 61.00K | 62.00K | 79.00K | - |
| Net Income | -1.82M | -19.66M | -12.53M | -18.89M | -20.84M | -32.09M | -33.82M | - | -55.34M | -66.10M | -65.02M | -69.39M | -74.11M | -85.85M |
| Diluted EPS | -1.45 | -9.46 | -2.51 | -3.78 | -0.51 | -0.64 | -0.60 | -0.86 | -0.93 | -1.11 | -1.08 | - | -1.06 | -1.14 |
| R&D Expense | 1.45M | 9.88M | 8.46M | 13.95M | 17.07M | 28.72M | 33.21M | 45.71M | 46.39M | 55.70M | 54.18M | - | 60.82M | 67.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 30.73M | 93.00M | 216.87M | 285.60M |
| Operating Income | -30.73M | -93.00M | -216.87M | -285.60M |
| EBITDA | -30.64M | -93.00M | -216.68M | -284.18M |
| Interest Expense | 9.15M | 0 | - | - |
| Pretax Income | -39.78M | -83.98M | -182.13M | -255.56M |
| Tax Provision | - | 0 | 18.00K | 278.00K |
| Net Income | -39.78M | -83.98M | -182.15M | -255.84M |
| Diluted EPS | -1.46 | -3.36 | -3.30 | -3.74 |
| R&D Expense | 27.79M | 68.42M | 167.87M | 214.71M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 152.06M | 401.40M | 753.95M | 937.13M |
| Current Assets | 152.06M | 398.41M | 529.71M | 741.36M |
| Cash & Equivalents | 151.89M | 118.32M | 141.79M | 131.55M |
| Inventory | - | - | - | - |
| Receivables | - | 1.21M | 4.70M | 5.96M |
| Total Liabilities | 9.98M | 21.49M | 37.16M | 33.25M |
| Current Liabilities | 9.98M | 20.56M | 28.56M | 27.91M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 2.03M | 11.83M | 8.85M |
| Total Equity | 0 | 379.91M | 716.79M | 903.88M |
| Shares Outstanding | 48.02M | 48.52M | 59.48M | 68.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -16.43M | -74.76M | -171.17M | -227.45M |
| Investing Cash Flow | 0 | -273.91M | -300.46M | -179.57M |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Capital Expenditure | - | -167.00K | -1.15M | -5.15M |
| Free Cash Flow | -16.43M | -74.93M | -172.33M | -232.60M |
| Net Change in Cash | 151.89M | -33.28M | 23.47M | -10.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | - | -22.1% | -25.4% | -28.3% |
| ROCE % | -21.6% | -24.4% | -29.9% | -31.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Venrock Adviser, LLC | 13.65% | 8.49M | $1.15B |
| 2 | Blackrock Inc. | 8.85% | 5.51M | $743.83M |
| 3 | HBK Investments L P | 4.58% | 2.85M | $384.95M |
| 4 | Vanguard Capital Management LLC | 4.14% | 2.57M | $347.42M |
| 5 | FMR, LLC | 4.01% | 2.49M | $336.75M |
| 6 | State Street Corporation | 3.69% | 2.30M | $310.36M |
| 7 | Driehaus Capital Management, LLC | 2.80% | 1.74M | $235.04M |
| 8 | Goldman Sachs Group Inc | 2.72% | 1.69M | $228.72M |
| 9 | Balyasny Asset Management LP | 2.68% | 1.67M | $224.91M |
| 10 | Glazer Capital LLC | 2.64% | 1.64M | $221.66M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for APGE
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQamhkeXFTdDJPM3lQOUJyd0FVOXhERXRobGc1VUFQTUpEVG9Vc3M0SW9xUXpTUkhLM0ExN05kZndYOVpuek1qMW9ZUWxhQi14SWpWMzhaOWUwS1FXU1Mta0VWdGsyd3JlZ0xvblZWcnZ0UWUzQjNBd0FuVnk4bnlRM1hjTF82RllUR0RnNk…
Stocks making the biggest moves premarket: Apogee Therapeutics, SpaceX, Arcosa & more - CNBC
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQVGpFMmJScFBSTEU5SkZXeEluaFQ4cHBPY1JmeXVUc2w5cDEyMHpQbUVpRE5GMl9wbUhqRzZqUFlnMkRnWERhNnItVzVmWDd0WWZmRU1nRDNadWNnQUhVNTN4NXhkaFJSOXVNZFRyb2pyalI5VGZRZFp0ODVxWURlZ0w0dDJpNUl6Q2Fta0…
Why Did APGE Stock Jump 22% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaTY1YlF4R3NrdW5ZYnRZSkptaUZuLWVuUl9SbjdaRE9XTk93MFlqTnB1c2ZteEk4Wm9qM3ExMVNMcUlnRTVkeDdzTGZvUDFUTUpiODVwOURNRF9jMDZSZjNuNUw1bjZURlpCX2xJM0c3Z1lEQWV1emVISk5XSGlRU0xPZ1hMdnY1UFhZdD…
APGE News | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE51TGVpaExSTjd1RjZxLVBkbW1BNjU2NWpscU1MWXBOeFRud3FqSWM3a2VfTTRKNWtXWWRWZksxQ2RxV0VEd2pnUmpoaWxwTjJGWmR5U0JMVzhqOUE?oc=5" target="_blank">APGE News | APOGEE THERAPEUTICS INC (NASDAQ:…
Apogee Therapeutics (APGE) Jumps Into Focus, Is The Stock Fully Valued? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNMERqVF9qeWFJYzNSVC1IalFGM1Fia1lWd3FRdEV6cDlfWUV0dy12ZFBNQVhTcjlxWnYwdWRGdVhZNnN5TkkxWEhOUWdIWjNFZG1jVFo4UHo4Qk94YndIUVNUdW9BY2JPLS15Y0FYckJhQ2w3UFdvQWJRTmVFRWgzOWJ1ajBTRkR5SDBNa1…
Apogee soars on AbbVie deal report; analysts bullish (ABBV:NYSE) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQcWRCV1Fla3pMcDE1M1AzSzljZnBOYnZkOWpTSm51eEJGSlVhS1V5VzRZSWVxcWI1aVhDYnJMa2pyWmRwQWlWeFVGY2J3TTFQOVpUMDYwSnFZMFRTdU1FY1hXLWpNRGJaQm55bmdnZVpkSEdwQllOaUdJOXA5ZTVURGlOUWZ0YktuSkFtSH…
APGE — Frequently Asked Questions
What is the current share price of Apogee Therapeutics Inc (APGE)?
As of 2026-10-23 16:27 PDT, Apogee Therapeutics Inc (APGE) trades at $135.07 on NasdaqGM. Its 52-week range is $36.02 to $135.08.
What is the market capitalisation of APGE?
Apogee Therapeutics Inc (APGE) has a market capitalisation of $8.40B on NasdaqGM.
What is the P/E ratio of APGE?
APGE trades at a trailing price-to-earnings (P/E) ratio of -31.12. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 8.49.
What is the return on equity (ROE) of APGE?
APGE has a return on equity (ROE) of -32.46%. Its return on capital employed (ROCE) is -31.41%.
Is APGE a good stock to buy?
This page provides a data-driven analysis of Apogee Therapeutics Inc (APGE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.